Oxford Biomedica (OTCMKTS:OXBDF) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, January 3rd.

Several other research analysts also recently weighed in on the stock. HC Wainwright reissued a “buy” rating on shares of Oxford Biomedica in a research note on Tuesday, October 31st. Zacks Investment Research downgraded shares of Oxford Biomedica from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st.

How to Become a New Pot Stock Millionaire

Oxford Biomedica (OTCMKTS:OXBDF) remained flat at $$0.17 during trading hours on Wednesday. The company’s stock had a trading volume of 834,500 shares, compared to its average volume of 102,593. Oxford Biomedica has a 1 year low of $0.04 and a 1 year high of $0.18.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Marea Informative and is the property of of Marea Informative. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.mareainformativa.com/2018/01/29/oxford-biomedica-oxbdf-downgraded-to-sell-at-valuengine-updated-updated-updated.html.

Oxford Biomedica Company Profile

Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.